Phase IIIa study shows benefits of IDegLira in T2D - Novo Nordisk

New Phase IIIa findings show IDegLira (insulin degludec plus liraglutide), from Novo Nordisk, for the treatment of people with Type 2 Diabetes, maintained its glucose-lowering effect and confirmed safety evaluations for up to one year. The DUAL I extension trial compared the efficacy and safety of IDegLira with insulin degludec and liraglutide alone in T2D insulin-na�ve adults. At 52 weeks, IDegLira demonstrated a statistically significant and sustained HbA1c reduction of 1.8% from baseline versus 1.4% for insulin degludec and 1.2% for liraglutide.

The average HbA1c at the end of the trial was 6.4% for IDegLira, 6.9% with insulin degludec and 7.1% with liraglutide. Of the patients on IDegLira, 78% achieved an HbA1c goal of less than 7% versus 63% for insulin degludec and 57% for liraglutide. Mean fasting plasma glucose was similar for IDegLira and insulin degludec and higher for liraglutide (103/108/132mg/dl respt). Findings from the 26-week extension of the DUAL I clinical trial programme were presented at the 74th Annual Scientific Sessions of the American Diabetes Association.